Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on September 04th, the Representative disclosed that they had sold between $1,001 and $15,000 in Kenvue stock on July 17th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
- Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
- Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
- Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
- Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
- Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
- Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
- Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
- Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
- Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.
Kenvue Stock Down 1.2%
Shares of KVUE stock traded down $0.23 during trading hours on Tuesday, reaching $18.51. The company had a trading volume of 2,847,106 shares, compared to its average volume of 27,628,561. The company has a market capitalization of $35.56 billion, a P/E ratio of 21.27, a price-to-earnings-growth ratio of 1.67 and a beta of 0.46. The stock’s fifty day simple moving average is $19.18 and its 200 day simple moving average is $18.26. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $20.13. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01.
Kenvue Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th were paid a dividend of $0.21 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.5%. The ex-dividend date was Wednesday, August 12th. Kenvue’s payout ratio is presently 96.55%.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of KVUE. Callan Family Office LLC acquired a new stake in shares of Kenvue during the second quarter valued at approximately $835,000. Calamos Advisors LLC boosted its stake in Kenvue by 24.1% in the 1st quarter. Calamos Advisors LLC now owns 3,351,000 shares of the company’s stock worth $57,771,000 after purchasing an additional 651,000 shares during the period. State of Wyoming grew its position in Kenvue by 233.5% during the 4th quarter. State of Wyoming now owns 97,992 shares of the company’s stock worth $1,690,000 after purchasing an additional 68,609 shares in the last quarter. Nuance Investments LLC purchased a new position in Kenvue during the 2nd quarter worth approximately $27,681,000. Finally, Nomura Asset Management Co. Ltd. raised its stake in Kenvue by 21.5% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 3,491,548 shares of the company’s stock valued at $60,229,000 after purchasing an additional 618,720 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on KVUE. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Barclays boosted their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, UBS Group cut their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus price target of $19.27.
Read Our Latest Stock Report on KVUE
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
Kenvue Company Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
See Also
- Five stocks we like better than Kenvue
- Safety Stocks Are Not What They Used to Be: 4 Names Built for a Weaker Dollar
- 3 AI Optical Networking Stocks Positioned for the Data Center Buildout
- 5 Defensive Stocks to Watch as CPI and the Fed Put the Rally to the Test
- Short Sellers Are Betting Against 3 AI Infrastructure Stocks—What Could Turn the Tide?
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
